London Pharmaceuticals and Research Corporation

Published purpose

The presented research program aims at developing water soluble derivatives of cannabinoids and their stable product formulations for health and medicinal applications. London Research and Pharmaceuticals Corporation (LRPC) developed a strategy to optimize the physicochemical and pharmacological properties of cannabinoids via providing new methods to convert cannabinoids (CBD) into fully soluble and stable products (Patent # US62/970,764) that are deliberately designed to impart specific properties that will be readily translated into nutraceuticals + pharmaceuticals and strengthen the health + wellness cannabis market where no fully soluble cannabinoids are known. The proposed project aims at scaling up the synthesis process and designing a validated manufacturing process of LRPC-soluble CBD. This is a major discovery with wide-reaching global implications including significant revenue potential across several multi-billion-dollar industries where LRPC would be first to market.